REFERENCES
- Leske M C, Sperduto R D. The epidemiology of senile cataracts: a review. Am J Epidemiol. 1983; 118: 152–165, [PUBMED], [INFOTRIEVE], [CSA]
- Hodge W G, Whitcher J P, Satariano W. Risk factors for age-related cataracts. Epidemiol. Rev. 1995; 17: 336–346, [PUBMED], [INFOTRIEVE], [CSA]
- Skalka H W, Prchal J T. Effect of corticosteroids on cataract formation. Arch Ophthalmol. 1980; 98: 1773–1777, [PUBMED], [INFOTRIEVE], [CSA]
- Glynn R J, Christen W G, Manson J E, Bernheimer J, Hennekens C H. Body mass index. An independent predictor of cataract. Arch Ophthalmol. 1995; 113: 1131–1137, [PUBMED], [INFOTRIEVE], [CSA]
- Harman D. Free radicals in aging. Mol Cell Biochem. 1988; 84: 155–161, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Spector A. Oxidative stress-induced cataract: mechanisms of action. FASEB J. 1995; 9: 1173–1182, [PUBMED], [INFOTRIEVE], [CSA]
- Dairou J, Malecaze F, Dupret J M, Rodrigues-Lima F. The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases (NAT) in human lens epithelial cells: inactivation by cellular oxidants and UVB-induced oxidative stress. Mol Pharmacol. 2005; 67: 1299–1306, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Dupret J M, Rodrigues-Lima F. Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. Curr Med Chem. 2005; 12: 311–318, [PUBMED], [INFOTRIEVE], [CSA]
- Payton M A, Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants. Biochem Pharmacol. 1988; 1: 361–366, [CSA]
- Lutz W. N-acetyltransferase genetic polymorphism and its role in the development of neoplastic disease. Med Pr. 2000; 51: 277–284, [PUBMED], [INFOTRIEVE], [CSA]
- Hickman D, Pope J, Patil S D, Fakis G, Smelt V, Stanley L A, Payton M, Unadkat J D, Sim E. Expression of arylamine N-acetyltransferase in human intestine. Gut. 1998; 42: 402–409, [PUBMED], [INFOTRIEVE], [CSA]
- Rodriquez J W, Kirlin W G, Ferguson V J, Doll M A, Gray K, Ruston T D, Lee M E, Kemp Urso K P. Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch Toxicol. 1993; 67: 445–452, [CSA], [CROSSREF]
- Hein D W, Doll M A, Fretland J A, Leff M A, Webb S J, Xiao G H, Devanaboyina U S, Nangju N A, Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphism. Cancer Epidemiol. 2000; 9: 29–42, [CSA]
- Filiadis I F, Georgiou I, Alamanos Y, Kranas V, Giannakopoulos X, Lolis D. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J Urol. 1999; 161: 1672–1675, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Borlak J T, Harsany V, Schneble H, Haegele K D. PNAT and CYP2D6 gene polymorphism in epileptic patients. Biochem Pharmacol. 1994; 48: 1717–1720, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Siegmund W, Fengler J D, Franke G, Zschiesche M, Eike O, Eike E, Meisel P, Wulkow R. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome. Br J Clin Pharmacol. 1991; 32: 467–472, [PUBMED], [INFOTRIEVE], [CSA]
- Baranova H, Canis M, Ivaschenko T, Albuisson E, Bothorishvilli R, Baranov V, Malet P, Bruhat M A. Possible involvement of arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 genes in the development of endometriosis. Mol Hum Reprod. 1999; 5: 636–641, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Longuemaux S, Delomenie C, Gallou C, Mejean A, Vincent-Viry M, Bouvier R, Droz D, Krishnamoorthy R, Galteau M M, Junien C. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res. 1999; 59: 2903–2908, [PUBMED], [INFOTRIEVE], [CSA]
- Morita S, Yano M, Tsujinaka T, Ogawa A, Taniguchi M, Kaneko K, Shiozaki H, Doki Y, Inoue M, Monden M. Association between genetic polymorphisms of glutathione S-transferase P1 and N-acetyltransferase 2 and susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer. 1998; 79: 517–520, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zielinska E, Niewiarowski W, Bodalski J, Stanczyk A, Bolanowski W, Rebowski G. Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases. Clin Pharmacol Ther. 1997; 62: 635–642, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tamer L, Tursen U, Eskandari G, Ates N A, Ercan B, Yildirim H, Atik U. N-acetyltransferase 2 polymorphisms in patients with Behcet's disease. Clin Exp Dermatol. 2005; 30(1)56–60, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- el-Yazigi A, Johansen K, Raines D A, Dossing M. N-acetylation polymorphism and diabetes mellitus among Saudi Arabians. J Clin Pharmacol. 1992; 32: 905–910, [PUBMED], [INFOTRIEVE], [CSA]
- Cascorbi I, Brockmoller J, Mrozikiewicz P M, Bauer S, Loddenkemper R, Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res. 1996; 56: 3961–3966, [PUBMED], [INFOTRIEVE], [CSA]
- Philip P A, Rogers H J, Millis R R, Rubens R D, Cartwright R A. Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur J Cancer Clin Oncol. 1987; 23: 1701–1706, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics. 1999; 9: 103–111, [PUBMED], [INFOTRIEVE], [CSA]
- Hadasova E, Brysova V, Kadlcakova E. N-acetylation in healthy and diseased children. Eur J Clin Pharmacol. 1990; 39: 43–47, [PUBMED], [INFOTRIEVE], [CSA]
- Chylack L T, Jr, Leske M C, McCarthy D, Khu P, Kashiwagi T, Sperduto R. Lens opacities classification system II (LOCS II). Arch Ophthalmol. 1989; 107: 991–997, [PUBMED], [INFOTRIEVE], [CSA]
- Meyer D, Parkin D P, Seifart H I, Maritz J S, Engelbrecht A H, Werely C J, van Helden P D. NAT2 slow acetylator function as arisk indicator for age-related cataract formation. Pharmocogenetics. 2003; 13: 285–289, [CSA], [CROSSREF]
- Hein D W, Rustan T D, Ferguson R J, Doll M A, Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamine by wild type and mutant recombinant human Nat1 and Nat2 acetyltransferases. Arch Toxicol. 1994; 68: 129–133, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Stanley L A, Copp A J, Pope J, Rolls S, Smelt V, Perry V H, Sim E. Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain. Teratology. 1998; 58(5)174–182, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]